Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-01-27
1999-06-29
Spivack, Phyllis
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3142
Patent
active
059169079
ABSTRACT:
Prevention or treatment of low renin hypertension by administration of an endothelin antagonist is disclosed.
REFERENCES:
patent: 2888455 (1959-05-01), Kano et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 4661479 (1987-04-01), Wyvratt, Jr. et al.
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 5236928 (1993-08-01), Chakravarty et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5571821 (1996-11-01), Chan et al.
patent: 5591761 (1997-01-01), Chan et al.
patent: 5594021 (1997-01-01), Chan et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5760038 (1998-06-01), Murugesan et al.
patent: 5780473 (1998-07-01), Murugesan et al.
Bird et al., Hypertension, vol. 25, Jun. 1995, p. 1191-1195.
S. Norio et al., Chemical Abstracts, vol. 70, No. 19, (1969), 87639g.
T. Saito, Chemical Abstracts, vol. 73, No. 23 (1970), 120511w.
Derwent Abstract No. 88-289069/41 Feb. 27, 1987.
Derwent Abstract No. 88-195835/28 Nov. 26, 1986.
Derwent Abstract No. 88-061295/09 Jul. 9, 1986.
Derwent Abstract No. 87-152485/22 Oct. 11, 1985.
Derwent Abstract No. 62299 E/30 Dec. 11, 1980.
Derwent Abstract No. 40927 D/23 Sep. 11, 1979.
Derwent Abstract No. 91-254550/35 Feb. 19, 1990.
Derwent Abstract No. 86-246709/38 Nov. 27, 1985.
Derwent Abstract No. 35012 K/15 Sep. 24, 1981.
Allen et al., CA116(11):106284Z, p. 778, 1992.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 11, (1969) 49825c.
R.D. Desai et al., Chemical Abstracts, vol. 71, No. 3, (1969) 12872q.
P. G. Ferrini et al., Angew. Chem. Internat. Edit., vol. 2, No. 2 (1963) p. 99.
A. M. van Leusen, et al., "Synthesis . . . Compounds", J. Org. Chem., vol. 41, No. 4, (1976), pp. 69-71.
W. J. Hammar et al., J. Heterocyclic Chem., vol. 18, (1981) pp. 885-888.
A. M. van Leusen et al., Tetrahedron Letters, No. 23, (1972), pp. 2369-2372.
Chan et al., "Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening", Biochemical and Biophysical Research Communications, vol. 201, No. 1, May 30, 1994, pp. 228-234.
Stein et al., "The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide", J. Med. Chem., vol. 37, No. 3, Feb. 4, 1994, pp. 329-331.
Doherty, J. Med. Chem., 35(9), 1493-1508 (May 1992).
CA 65: 2241d (1966).
CA 92:41908v (1979).
Wang et al., "Nitrile . . . sinomin," CA 108:94444w, p. 651 (1988).
Khanna, "Oral . . . formulation," CA 115:35728p, p. 415 (1991).
Stein et al., "The Discovery . . . 1-naphthalenesulfonamide," CA 120:18233n, p. 21-22 (1994).
Vree et al., "Renal excretion . . . function," CA 97:84685r, p. 23 (1982).
Oie, "Pharmacokinetics . . . dosing," CA102:197512x, p. 18 (1985).
Murugesan et al., "N-(heteroaryl) . . . antagonists," CA 120:270370c, p. 1067 (1994).
Ihara et al., Life Sciences, vol. 50, pp. 247-255 (1991).
Reynolds et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 273(3), 1410-1417 (1995).
Williams et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 275(3), 1518-1526 (1995).
Ohlstein et al., Proc. Natl. Acad. Sci., vol. 91, pp. 8052-8056 (1994).
Ohlstein et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 276(2), 609-615 (1996).
Opgenorth et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 276(2), 473-481 (1996).
Masuda et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 279(2), 675-685 (1996).
Clozel et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 270(1), 228-235 (1994).
Ergul et al., Hypertension, pp. 652-655 (Oct. 1996).
King, A. J., B. M. Brenner, and S. Anderson. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am. J. Physiol. 256:F1051-1058, 1989.
Cao, L. and R. O. Banks. Cardiorenal actions of endothelin, Part I: Effects of converting enzyme inhibition. Life Sci. 46:577-583, 1990.
Cargnelli, G., G. Rossi, S. Bova and A. C. Pessina. In vitro vascular reactivity to endothelin: A comparison between young and old normotensive and hypertensive rats. Clin. and Exper. Hyper.-Theory and Practice. A12(8):1437-1451, 1990.
Tomobe, Y. T. Miyauchi, A. Saito, M. Yanigasawa, S. Kimura, K. Goto and T. Masaki. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur. J. Pharmac. 152: 373-374, 1988.
Suzuki, N., T. Miyauchi, Y. Tomobe, H. Matsumoto, K. Goto, T. Masaki, and M. Fujino. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Bioc. Bioph. Res. Comm. 167(3):941-947, 1990.
Goligorsky, M. S., K. Iijima, M. Morgan, M. Yanigasawa, T. Masaki, L. Lin, A Nasjletti, M. Frazer, and K. Badr. Role of endothelin in the development of Dahl hypertension. J. Vasc. Med. and Biol. 2(4): 185A, 1990.
McMahon, E.G., Palomo, M.A., Moore, W.M., J. Cardiovasc. Pharmacol.; 17 Supp 7: S29-33 (1991).
Babajko Suzanne E.
Bristol--Myers Squibb Company
Davis Stephen B.
Spivack Phyllis
LandOfFree
Method for preventing or treating low renin hypertension by admi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or treating low renin hypertension by admi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or treating low renin hypertension by admi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375662